The Erdelyi group has studied the binding of our inhibitors in VIM-2.

Wieske LHE, Bogaerts J, Leding AAM, Wilcox S, Rasmussen AA, Leszczak K, Turunen L, Herrebout WA, Hubert M, Bayer A, Erdélyi M. ACS Med. Chem. Lett., 2022, 257-61. NMR Backbone Assignment of VIM-2 and Identification of the Active Enantiomer of a Potential Inhibitor. doi: 10.1021/acsmedchemlett.1c00635